Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy

HIV Clinical Trials

Volumn 10, Issue 3, 2009, Pages 135-142

  Shuter, Jonathan ^a,b   Sarlo, Julie A ^a   Rode, Richard A ^c   Zingman, Barry S ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Adherence; Dose staggering; HIV; MEMS; Ritonavir; Selective

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; EFAVIRENZ; RITONAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MEDICAL INFORMATICS APPLICATIONS; MEDICATION ADHERENCE; MIDDLE AGED; NEW YORK CITY; OLIGOPEPTIDES; PHOSPHORIC ACID ESTERS; PROSPECTIVE STUDIES; PYRIDINES; QUESTIONNAIRES; RITONAVIR; SULFONAMIDES; VIRAL LOAD;

EID: 69249096565     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1003-135     Document Type: Article

References (16)

1. Washington CB, Flexner C, Sheiner LB, et al. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther. 2003;73:406-416
2. Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother. Sept 25, 2007. E-pub ahead of print.
3. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self report and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423.
4. McNabb JJ, Nicolau DP, Stoner JA, et al. Patterns of adherence to antiretroviral medications: the value of electronic monitoring. AIDS. 2003;17:1763-1767.
5. Chesney MA, Ickovics JR, Chambers DB, et al. Selfreported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255-266.
6. Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr. 2005;40:294-300.
7. Kastrissios H, Suarez JR, Hammer S, Katzenstein D, Blaschke TF. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. AIDS. 1998;12:2305-2311.
8. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
9. McNabb JJ, Nicolau DP, Stoner JA, Ross J. Patterns of adherence to antiretroviral medications: the value of electronic monitoring. AIDS. 2003;17:1763-1767.
10. MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase as initial therapy (CPCRA 058 FIRST study): a long-term randomized trial. Lancet. 2006;368:2125-2135.
11. Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure and resistance. AIDS. 2008;22:75-82.
12. Gross R, Yip B, Wood E, et al. Boosted protease inhibitors are more forgiving of suboptimal adherence than nonboosted protease inhibitors or non-nucleoside reverse transcriptase inhibitors. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Abstract K-210.
13. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates below 95%. J Acquir Immune Defic Syndr. 2007;45:4-8.
14. Bartlett JG. International workshop on management of treatment experienced patients. Hopkins HIV Rep. 2002;14:4-5.
15. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
16. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.